NCT06751277View on ClinicalTrials.gov

QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

July 30, 2027

Conditions
Recurrent or Metastatic Endometrial Cancer
Interventions
DRUG

QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706

QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

lead

xiang yang

OTHER